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ABSTRACT
Perfluoroalkyl substances (PFASs) are highly persistent chemicals that might be associated with asthma
and allergy, but the associations remain unclear. Therefore, this study examined whether pre- and postna-
tal PFAS exposure was associated with childhood asthma and allergy. Measles, mumps, and rubella (MMR)
vaccination in early life may have a protective effect against asthma and allergy, and MMR vaccination is
therefore taken into account when evaluating these associations. In a cohort of Faroese children whose
mothers were recruited during pregnancy, serum concentrations of five PFASs – Perfluorohexane sulfonic
acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid
(PFNA), and perfluorodecanoic acid (PFDA) – were measured at three timepoints (maternal serum in preg-
nancy week 34–36 and child serum at ages 5 and 13 years) and their association with immunoglobulin E
(IgE) (cord blood and at age 7 years) and asthma/allergic diseases (questionnaires at ages 5 and 13 years
and skin prick test at age 13 years) was determined. A total of 559 children were included in the analyses.
Interactions with MMR vaccination were evaluated. Among 22 MMR-unvaccinated children, higher levels
of the five PFASs at age 5 years were associated with increased odds of asthma at ages 5 and 13. The
associations were reversed among MMR-vaccinated children. Prenatal PFAS exposure was not associated
with childhood asthma or allergic diseases regardless of MMR vaccination status. In conclusion, PFAS
exposure at age 5 was associated with increased risk of asthma among a small subgroup of MMR-unvac-
cinated children but not among MMR-vaccinated children. While PFAS exposure may impact immune sys-
tem functions, this study suggests that MMR vaccination might be a potential effect-modifier.
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Introduction
Perfluoroalkyl substances (PFAS) constitute a group of highly
persistent chemicals used in a variety of products including fur-
niture, carpets, clothing, food packaging, and firefighting foams
(Fromme et al. 2009). PFAS are found in human serum world-
wide (Houde et al. 2006), and children appear to have a greater
exposure than teenagers and adults (Trudel et al. 2008; Kato
et al. 2009). Recently, higher serum-PFAS concentrations in
childhood have been associated with increased odds of concur-
rent asthma (Dong et al. 2013), perhaps due to a shift toward a
T-helper type 2 cell (TH2) immune response (Dong et al. 2011)
as seen in allergic asthma and allergic diseases. However, other
studies could not replicate this association (Humblet et al. 2014;
Stein et al. 2016). Reported associations between prenatal PFAS
exposure and asthma, wheezing, and other allergic diseases in
children also have not been consistent (Wang et al. 2011; Okada
et al. 2012, 2014; Granum et al. 2013; Smit et al. 2015).
Furthermore, measles, mumps, and rubella (MMR) vaccin-
ation in early life may have a protective effect against asthma or
asthma symptoms (Gruber et al. 2003; Roost et al. 2004), an
association that was substantiated in our previous analyses
(Timmermann et al. 2015). The protective effect is possibly due
to the elicitation of a TH1-biased response (Pabst et al. 1997;
Ovsyannikova et al. 2003), and it is possible that a TH1-biased
response induced by MMR vaccination could suppress a PFAS-
induced TH2 immune response thus minimizing the effect of
PFAS on asthma among MMR-vaccinated children.
The objective of the present study was therefore to investigate
whether pre- or postnatal PFAS exposure was associated with
asthma and allergic diseases in a birth cohort while considering
the potential effect modification by MMR vaccination.
Materials and methods
Sample population
Data were collected as part of the Children’s Health and
Environment in the Faroe Islands (CHEF) study (Grandjean
et al. 2010; Heilmann et al. 2010; Timmermann et al. 2015). The
birth cohort was formed in 1997–2000, and a blood sample for
measuring environmental exposures was obtained when the
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women were included in gestational week 34–36. Obstetric infor-
mation was recorded, and a cord blood sample was obtained at
birth. At ages 5, 7, and 13 years, children were invited for phys-
ical examinations (including blood sampling), and parents filled
out a questionnaire together with a research nurse.
MMR vaccinations were routinely administered at 15months-
of-age; vaccination dates were obtained from the child’s vaccin-
ation card at age 5. There were no specific contraindications
against the vaccination. Children were considered eligible for this
study if they attended the age-5 examination. They were excluded
if they had had measles or if no information was provided about
this disease (Timmermann et al. 2015).
Written informed consent was obtained from the parents of
all children included in the study. The study was carried out in
accordance with the Helsinki Declaration and was approved by
the Ethical Review Committee serving the Faroe Islands and the
U.S. (Harvard) Institutional Review Board (IRB).
Asthma and allergy outcomes
Total Immunoglobulin E (IgE) and A (IgA) concentrations were
quantified in cord blood by ImmuniCAP and in-house ELISA.
Analyses have been described in more detail elsewhere
(Timmermann et al. 2015). IgE measures from samples with IgA
concentrations >50 lg/ml were disregarded due to possible con-
tamination with maternal blood (Bonnelykke et al. 2010). At age
5, parents were asked whether the child had been diagnosed with
or was suspected to suffer from asthma and whether the child
had been diagnosed with hypersensitivity or allergy. At age 7, a
blood sample was drawn from which total IgE was quantified. At
age 13, parents were asked whether the child had ever suffered
from asthma. Rhinoconjunctivitis symptoms (in past 12 months)
and eczema (ever) were also identified through the parental ques-
tionnaire using questions from the International Study of
Asthma and Allergies in Childhood (ISAAC) as previously
described (Timmermann et al. 2015). The children underwent a
skin prick test (SPT) with extracts (Soluprick, ALK, Hørsholm,
Denmark) of five common allergens (birch/grass pollen, dog/cat
dander, and house dust mite [Dermatophagoides pteronyssinus])
at age 13. A wheal size 3mm in diameter resulting from any of
the five allergens was considered positive.
PFAS analysis
Perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic
acid (PFOS), perfluoro-octanoic acid (PFOA), perfluorononanoic
acid (PFNA), and perfluorodecanoic acid (PFDA) were measured
in maternal pregnancy serum and child serum at ages 5 and 13
(Grandjean et al. 2012). Analyses were carried out by isotope
dilution and online solid-phase extraction followed by high per-
formance liquid chromatography with triple quadropole mass-
spectrometric analysis according to the methods of Haug et al.
(2009). PFOS was quantified by integration of two adjacent
peaks, which represent the branched isomers and the linear iso-
mer. The between batch-imprecision was < 7.7%, and the limit
of detection (LOD) for the five PFAS was 0.03 ng/ml. All five
PFAS were found at concentrations above the LOD in all mater-
nal and child serum samples.
Potential confounders
Information about variables known to be associated with asthma
and/or allergic diseases (Bodner et al. 1998; Reichman and
Nepomnyaschy 2008; Just et al. 2010; Nagel et al. 2010; Civelek
et al. 2011; Herr et al. 2012; Chang et al. 2013; de Vries et al.
2014; Dogaru et al. 2014; Mu et al. 2014; Netting et al. 2014) was
obtained from the recruiting midwife’s chart (maternal pre-preg-
nancy BMI (weight/height2), maternal smoking during pregnancy
(none/any), premature birth (< 37 weeks/ 37 weeks), birth sea-
son (spring: March–May; summer: June–August; fall:
September–November; winter: December–February), sex, birth
weight, and parity (zero/one/more than one previous birth), the
parental questionnaires at age 5 (total duration of breastfee-
ding¼ exclusive and partial breastfeeding in months, number of
siblings, parental smoking at home [yes/no], weekly fish dinners,
and daycare attendance [yes/no]) and age 13 (fish dinners,
domestic pets, and family history of asthma and allergic diseases
[no/from one parent’s side/from both parents’ sides]).
Statistics
Among children included in this study, all missing values were
imputed using multiple imputation by chained equations with 40
imputations based on all exposures, outcomes, and potential con-
founders, as well as three auxiliary variables (Azur et al. 2011),
i.e., information about the father’s primary education (7–8th
Grade/9–10th Grade), whether the child had lived abroad
between ages 7 and 13 (yes/no), and whether the child is allergic
to anything (yes/no or do not know). IgE and PFAS concentra-
tions were right skewed and therefore were log10–transformed to
avoid violating model assumptions when performing imputations
and conducting association analyses.
Each interaction between MMR vaccination and PFAS con-
centration measures was tested in relation to all asthma and
allergic disease measures (except cord blood IgE, which could
not have been affected by subsequent MMR vaccination) in mar-
ginal analyses using the unimputed data. Interactions considered
to be consistent (interactions with p< .2 in the same direction
for at least three out of five PFAS measures) were included in
the imputation of the asthma and allergic disease measures on
which they were found to interact.
All imputations were performed using the mi impute chained
command in Stata version 14.0 (StataCorp, College Station, TX).
The imputation models are described in further detail in
Appendix A. Using the imputed data, associations between serum
concentrations of each PFAS and asthma and allergic diseases at
ages 5 and 13 were determined in logistic regression models, and
associations between each PFAS and total IgE in cord blood and
at age 7 were determined in linear regression models. If interac-
tions were identified in the marginal analyses using the unim-
puted data, an interaction term for PFAS exposure and MMR
vaccination was included in the model, and potential confound-
ers were included if associated with the PFAS measures
(Appendix B). When investigating interactions, information
about birth weight and family history of chronic bronchitis/
asthma was also included in the models because these factors are
associated with MMR vaccination uptake in the Faroese cohort
and so might confound the association between MMR vaccin-
ation and asthma/allergic diseases (Timmermann et al. 2015).
Since both PFAS concentrations and IgE measures were log-
transformed, the estimates of association were converted to
express the percent change in IgE associated with a doubled
serum-PFAS concentration in the linear regression models and
the odds ratio with a doubling of the PFAS exposure in the logis-
tic regression models.
Sensitivity analyses were also performed in which analyses
were conducted using the unimputed data, and information
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about maternal education (none/any education above primary
school), maternal pregnancy serum dichlorodiphenyldichloro-
ethylene (DDE), and the sum of maternal pregnancy serum poly-
chlorinated biphenyl (PCB) concentrations was included one at a
time. A simplified sumPCB concentration was calculated as the
sum of congeners CB-138, CB-153, and CB-180 – multiplied by
2. Last, subgroup analyses were performed separately comparing
children with atopic and nonatopic asthma to children with no
asthma. At age 5, atopic asthma was classified as having both
asthma and allergy (41% of asthma cases), and at age 13, atopic
asthma was classified as having both asthma and positive SPT
(59% of asthma cases). In these analyses, only children with com-
plete information about both asthma and allergy/SPT were
included. All analyses were performed in Stata version 14.0.
Results
Informed consent was obtained from 648 mothers of whom 8
had twins, thus leaving 640 singleton children. Among these,
59 children were not seen at age 5, and 22 were excluded due
to having a history of measles infection (n¼ 7) or not having
provided information about measles infection (n¼ 15)
(Timmermann et al. 2015), leaving 559 children (87%) eligible
for the study (Figure 1). The 81 (59þ 22) ineligible children had
mothers with lower parity. Furthermore, among the ineligible
children, mothers of 76 children had provided a blood sample in
which PFAS was measured. These 76 mothers had lower serum
concentrations of PFDA and PFNA, and higher levels of PFOA.
Finally, 31 of the ineligible children attended the 13-year examin-
ation. These 31 children more often had asthma at age 13 com-
pared to the 491 (522–31) children who attended the 13-year
examination and were eligible for the study. No other significant
(p< .05) differences between the eligible and ineligible children
were found with regard to outcomes, exposures, or potential
confounders.
The distributions of exposures, outcomes, and potential con-
founders are shown in Table 1. Among the 559 mothers included
in this study, 30 did not provide a blood sample for PFAS ana-
lysis during pregnancy. Furthermore, 35 children did not provide
a blood sample for PFAS analysis at age 5, and 68 children did
not participate in the examination at age 13. An additional six
children did not provide a blood sample for PFAS analysis at age
13. These missing values were imputed along with missing infor-
mation about the outcomes and covariates. In the unimputed
data, the median PFHxS and PFOS concentrations were highest
(4.5 and 27.4 ng/ml) in maternal pregnancy serum and lowest
in child serum at age 13, while the medians for PFOA and
PFNA were highest in age-5 child serum (4.0 and 1.0 ng/ml);
PFDA concentrations were stable across the three timepoints
SINGLETON CHILDREN: 
640 
ATTENDED 5-YEAR EXAMINATION /  
ANSWERED 5-YEAR QUESTIONNAIRE: 
581 
NOT SEEN AT AGE 5 (N=59):  
Withdrawn from the study: 17 
Living abroad: 31 
Non-participating this time: 9 
Died: 2 
CHILDREN INCLUDED  
IN THE COHORT: 
656 
ATTENDED 7-YEAR 
EXAMINATION: 
566 
ATTENDED 13-YEAR 
EXAMINATION: 
522 
ELIGIBLE CHILDREN ATTENDING 
7-YEAR EXAMINATION: 
522 
ELIGIBLE CHILDREN ATTENDING 
13-YEAR EXAMINATION: 
491 
NOT SEEN AT AGE 13 (N=118):  
Withdrawn from the study: 29 
Living abroad: 39 
Non-participating this time: 39 
Lost to follow-up: 3 
Died: 4 
No participation since birth (not invited): 4 
NOT SEEN AT AGE 7 YEARS (N=74):  
Withdrawn from the study: 24 
Living abroad: 10 
Non-participating this time: 37 
Died: 3 
NO PREVIOUS MEASLES INFECTION: 
559 
History of measles infection: 7     
No information about measles infection: 15   
Figure 1. Flowchart of the experiment.
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(0.3 ng/ml). At age 5, 14.2% and 13.5% were reported to have
asthma and allergy, respectively; at age 13, 16.9% had had
asthma, 38.7% had a positive SPT, 12.0% had allergic rhinocon-
juctivitis, and 20.8% had had eczema. Only 22 out of 555 chil-
dren had not received the MMR vaccination scheduled for age
15 months before the 5-year examination (Table 1). PFAS distri-
butions including minimum and maximum values for children
with and without asthma at ages 5 and 13 years by MMR vaccin-
ation status are shown in Appendix C. None of the small sub-
groups contain extreme values. As previously shown, children
without MMR vaccination had higher risk of asthma and allergic
diseases (Timmermann et al. 2015).
In the marginal analyses on the unimputed data, no MMR-
vaccination interaction with maternal PFAS concentrations was
found in relation to any of the outcome measures, but interac-
tions between MMR vaccination and age-5 or age-13 PFAS in
relation to some of the asthma and allergic disease measures
were observed. Thus, increased serum-PFAS concentrations at
age 5 tended to be associated with higher odds of a history of
asthma at ages 5 and 13 and allergy at age 5 among the MMR-
unvaccinated children, and among MMR-vaccinated children, an
increase in serum-PFAS concentrations at age 5 tended to be
associated with reduced odds of history of asthma at ages 5 and
13 and allergy at age 5. Few of these associations were, however,
significant; the interaction between MMR vaccination and PFASs
at age 5 was significant for PFOA in relation to asthma at ages 5
and 13 and for PFNA and PFDA in relation to asthma at age 5.
The same pattern was found in the association between PFAS
concentrations at age 13 and atopic eczema at age 13 (data not
shown).
When using the data with imputations and taking potential
confounding factors into account, the pattern described above
persisted. As shown in Table 2, a doubling of the serum-PFOA
concentration at age 5 was significantly associated with 10-fold
increased odds of asthma at ages 5 and 13 among the MMR-
unvaccinated children. A doubling of the age 5 serum-PFNA
concentration was likewise significantly associated with similarly
increased odds of asthma at both ages among the MMR-unvac-
cinated children, and a doubling of the age 5 serum-PFDA con-
centration showed a significant, though slightly weaker,
association with asthma at age 5 among the MMR-unvaccinated
children (Table 2). The interaction between MMR vaccination
and age-5 PFAS was significant for PFOA, PFNA, and PFDA in
relation to asthma at ages 5 and 13 and for PFHxS in relation to
asthma at age 5 (Table 2). Results were similar when maternal
education, pregnancy serum-DDE, or pregnancy serum-PCB con-
centrations were included in an analysis using the unimputed
data (results not shown).
In the adjusted analyses, in which interactions with MMR vac-
cination were not included (because no interaction was found in
the marginal analyses), no clear patterns of association were
found. Specifically, no associations were found between PFAS
exposure at age 5 and total IgE at age 7, positive SPT at age 13,
allergic rhinoconjunctivitis at age 13, or atopic eczema at age 13
(Table 2). Increased maternal serum-PFHxS concentrations were
associated with increased odds of atopic eczema at age 13 (Table
3), but given the large number of analyses conducted, the risk of
Type I errors was increased and this one significant association
was likely a chance finding. No associations were found between
maternal PFAS exposure and the other outcome measures (Table
3). Additionally, increased serum-PFHxS and serum-PFNA con-
centrations at age 13 were associated with reduced odds of
asthma and allergic rhinoconjunctivitis, respsectively (Table 4).
However, since no other significant associations were found with
PFAS exposure at age 13, these associations could also have been
chance findings.
Table 2. Differences in IgE (%) and OR for history of asthma, history of allergic diseases, and SPT associated with a doubling of serum-PFAS concentrations at age 5.
N ¼ 559 Age 5 Age 7
Age 5
PFAS
MMR vaccination
before age 5
Asthmaa Allergya IgE
OR (95% CI) pi OR (95% CI) pi % difference (95% CI)
PFHxS no 3.57 (0.95; 13.43) 0.03 1.25 (0.41; 3.88) 0.56 2.88 (20.47; 18.61)
yes 0.81 (0.58; 1.14) 0.89 (0.63; 1.25)
PFOS no 3.96 (0.55; 28.39) 0.18 6.15 (0.77; 49.23) 0.06 9.38 (37.17; 30.71)
yes 0.98 (0.55; 1.76) 0.80 (0.43; 1.49)
PFOA no 10.37 (1.06; 101.93) 0.03 1.73 (0.32; 9.22) 0.21 7.87 (25.22; 55.61)
yes 0.76 (0.41; 1.39) 0.55 (0.29; 1.06)
PFNA no 12.52 (1.29; 121.67) 0.02 2.40 (0.57; 10.03) 0.11 5.02 (27.83; 25.00)
yes 0.72 (0.44; 1.18) 0.71 (0.43; 1.17)
PFDA no 4.04 (1.05; 15.50) 0.02 2.21 (0.69; 7.06) 0.10 7.59 (26.58; 16.29)
yes 0.71 (0.48; 1.06) 0.79 (0.52; 1.19)
Age 13
Age 5 Asthmaa
Positive skin
prick test
Allergic rhinoconjunctivitis
(past 12 months)
Atopic
eczema
PFAS OR (95% CI) pi OR (95% CI) OR (95% CI) OR (95% CI)
PFHxS no 2.51 (0.77; 8.16) 0.10 0.95 (0.75; 1.20) 0.80 (0.57; 1.14) 0.92 (0.70; 1.22)
yes 0.90 (0.63; 1.27)
PFOS no 5.41 (0.62; 47.16) 0.12 0.76 (0.49; 1.18) 0.63 (0.33; 1.20) 0.80 (0.46; 1.39)
yes 0.94 (0.51; 1.74)
PFOA no 9.92 (1.06; 93.22) 0.02 1.15 (0.75; 1.77) 1.01 (0.54; 1.89) 0.72 (0.42; 1.25)
yes 0.65 (0.35; 1.20)
PFNA no 6.85 (1.05; 44.69) 0.02 0.79 (0.57; 1.10) 0.63 (0.37; 1.07) 0.79 (0.51; 1.23)
yes 0.71 (0.44; 1.16)
PFDA no 2.87 (0.84; 9.79) 0.03 0.79 (0.59; 1.05) 0.71 (0.47; 1.08) 0.92 (0.64; 1.31)
yes 0.71 (0.48; 1.06)
Missing values were imputed using multiple imputation. All analyses were adjusted for family history of eczema in children, allergic eczema, and hay fever, maternal
pre-pregnancy BMI, maternal smoking during pregnancy, sex, duration of breastfeeding, fish intake at age 5, number of siblings, and daycare attendance at age 5.
aAdditionally adjusted for birth weight, and family history of chronic bronchitis/asthma.
ip-value for PFAS/MMR vaccination interaction.
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When dividing asthma into atopic and nonatopic asthma, the
interactions between MMR vaccination and PFAS at age 5 per-
sisted for atopic asthma, whereas no significant interactions or
associations were seen for nonatopic asthma (Table 5). Among
MMR-unvaccinated children, a doubling in the concentration of
the PFASs at age 5 was significantly associated with 9–75-fold
higher odds of atopic asthma at age 5, and a doubling of the
PFNA concentration was likewise significantly associated with 7-
fold higher odds of atopic asthma at age 13 (Table 5).
Discussion
Serum-PFAS concentrations at age 5 were associated with
increased odds of asthma history at ages 5 and 13 in children
who had not been MMR vaccinated, although the numbers were
small. The associations were reversed among MMR-vaccinated
children. The same tendencies, though not significant, were seen
in the association between serum-PFAS at age 5 and history of
allergy at age 5 and between serum-PFAS at age 13 and history
of atopic eczema at age 13.
A Taiwanese case-control study reported that increased
PFAS exposures were associated with concurrent asthma among
10–15-year-olds (Dong et al. 2013), while a cross-sectional study
using the U.S. National Health and Nutrition Examination
Survey (NHANES) data (1999–2000, 2003–2004, 2005–2006,
2007–2008) of 12–19-year-olds found that serum-PFOA was
associated with increased odds of asthma while PFOS showed a
negative association (Humblet et al. 2014), and finally a recent
study using NHANES data (2005–2006) of 12–19-year-olds did
not find any association between PFAS and asthma but found
that higher serum-PFOS concentrations were associated with
reduced odds of sensitization to any allergen, while increased
PFOA and PFNA were associated with increased serum IgE (Stein
et al. 2016). Neither of these studies examined MMR vaccinations
or other factors that might contribute to the different findings.
In regard to prenatal PFAS exposure, cord blood PFOS and
PFOA concentrations have been found to correlate positively
with cord blood IgE levels in boys (Wang et al. 2011), while high
maternal PFOA concentrations were associated with decreased
cord blood IgE levels in girls (Okada et al. 2012) and reduced
risk of allergic diseases during the first 24 months (Okada et al.
2014). Recent studies found that maternal PFOA concentrations
were inversely associated with current wheezing among
Ukrainian but not in Greenlandic children aged 5–9 years (Smit
et al. 2015), and other types of maternal PFAS were inversely
Table 3. Differences in IgE (%) and OR for history of asthma, history of allergic diseases, and SPT associated with a doubling of maternal serum-PFAS
concentrations.
N¼ 559 Cord blood Age 5 Age 7
Maternal PFAS
IgE Asthma Allergy IgE
% difference (95% CI) OR (95% CI) OR (95% CI) % difference (95% CI)
PFHxS 0.17 (-9.33; 9.93) 0.99 (0.80; 1.22) 1.20 (0.95; 1.53) 6.35 (6.89; 21.48)
PFOS 6.28 (30.29; 25.99) 1.21 (0.64; 2.29) 0.73 (0.38; 1.41) 18.61 (24.06; 85.24)
PFOA 2.81 (19.29; 30.93) 1.37 (0.81; 2.32) 0.92 (0.53; 1.57) 5.15 (31.92; 32.14)
PFNA 0.94 (17.67; 23.75) 1.03 (0.67; 1.59) 0.82 (0.52; 1.31) 21.11 (11.70; 66.12)
PFDA 3.23 (14.29; 24.35) 1.09 (0.72; 1.65) 0.83 (0.54; 1.27) 24.73 (5.68; 64.94)
Age 13
Asthma Positive skin prick test Allergic rhinoconjunctivitis (past 12 months) Atopic eczema
Maternal PFAS OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
PFHxS 0.98 (0.79; 1.20) 0.94 (0.79; 1.12) 1.14 (0.88; 1.46) 1.32 (1.08; 1.62)
PFOS 1.61 (0.84; 3.08) 1.25 (0.75; 2.11) 1.05 (0.51; 2.17) 0.75 (0.42; 1.34)
PFOA 1.12 (0.67; 1.88) 1.16 (0.76; 1.77) 1.18 (0.65; 2.15) 1.36 (0.85; 2.19)
PFNA 1.21 (0.77; 1.88) 0.97 (0.69; 1.38) 0.86 (0.52; 1.41) 0.81 (0.55; 1.20)
PFDA 1.26 (0.83; 1.92) 1.02 (0.74; 1.41) 0.88 (0.56; 1.38) 0.92 (0.64; 1.32)
Missing values were imputed using multiple imputation. All analyses were adjusted for maternal parity, family history of eczema in children, allergic eczema and hay
fever, maternal pre-pregnancy BMI, maternal smoking during pregnancy, maternal fish intake during pregnancy, and duration of breastfeeding.
Table 4. OR for history of asthma, history of allergic diseases, and SPT associated with a doubling of serum-PFAS concentrations at age 13.
N¼ 559 Age 13
Age 13 PFAS
MMR vaccination
before age 5
Atopic eczemaa
Asthma Positive skin prick test
Allergic rhinoconjunctivitis
(past 12 months)
OR (95% CI) pi OR (95% CI) OR (95% CI) OR (95% CI)
PFHxS no 1.27 (0.16; 10.15) 0.66 0.63 (0.41; 0.97) 0.88 (0.64; 1.21) 0.91 (0.58; 1.43)
yes 0.80 (0.53; 1.20)
PFOS no 8.94 (0.27; 299.11) 0.18 0.69 (0.43; 1.09) 0.90 (0.63; 1.29) 0.66 (0.39; 1.11)
yes 0.82 (0.53; 1.28)
PFOA no 4.48 (0.42; 47.69) 0.17 0.93 (0.57; 1.53) 1.03 (0.70; 1.51) 0.69 (0.40; 1.20)
yes 0.82 (0.49; 1.36)
PFNA no 371.98 (0.16; 8.62105) 0.12 0.81 (0.52; 1.28) 0.82 (0.57; 1.16) 0.55 (0.32; 0.94)
yes 0.77 (0.49; 1.22)
PFDA no 401.88 (0.09; 1.84106) 0.15 0.84 (0.55; 1.29) 0.81 (0.59; 1.13) 0.68 (0.42; 1.12)
yes 0.88 (0.58; 1.34)
Missing values were imputed using multiple imputation. All analyses were adjusted for family history of eczema in children, allergic eczema and hay fever, maternal
pre-pregnancy BMI, maternal smoking during pregnancy, sex, duration of breastfeeding, and fish intake at age 13.
aAdditionally adjusted for birth weight, and family history of chronic bronchitis/asthma.
ip-value for PFAS/MMR vaccination interaction.
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associated with allergic diseases among 4-year-old children
(Goudarzi et al. 2016). Several other analyses, however, showed
no associations between prenatal exposure to PFAS and cord
blood IgE (Ashley-Martin et al. 2015) or asthma and allergy in
childhood (Wang et al. 2011; Okada et al. 2012; Granum et al.
2013), which is in accordance with the current findings.
The mechanisms underlying immunomodulating effects of
various PFAS are far from fully understood, but these chemicals
have been shown to affect activation of human immune cells and
reduce both pro- and antiinflammatory cytokine production in
vitro (Corsini et al. 2014). In mice, PFOS exposure has been
shown to lead to an increase in interleukin (IL)-4 and IL-10 and
to decrease IL-2 and interferon (IFN)-c, thereby indicating a shift
toward a TH2 immune response (Dong et al. 2011). If such a
shift occurs, it could perhaps explain the positive association
between serum-PFAS concentrations and asthma among the
MMR-unvaccinated children in the current analyses, while the
MMR vaccination may rather shift the immune response toward
a more TH1-prone state (Pabst et al. 1997; Ovsyannikova et al.
2003), thereby preventing or counteracting a PFAS-induced TH2-
shift. If PFAS exposure affects the TH1/TH2 balance, an inter-
action between MMR vaccination and serum-PFAS concentra-
tions thus seems plausible.
If MMR vaccination modifies the effect of PFAS on asthma as
suggested by the current findings, differences in vaccination
schedules might explain why the association between PFAS
exposure and asthma differs between studies from different parts
of the world. However, the range of serum-PFAS concentrations
is also important. Both the age 5- and 13-year serum-PFAS con-
centrations of children in this study were lower than among
Taiwanese children, except for PFOA, which was higher (Dong
et al. 2013), and the age 5 serum-PFAS concentrations were simi-
lar to those of American children whereas the age 13 serum-
PFAS concentrations were lower in the present study (Humblet
et al. 2014). It is possible MMR vaccination can protect against
adverse effects of PFAS on asthma only when PFAS concentra-
tions are relatively low.
It is important to note that a main limitation of this study
is that very few cohort children were not MMR vaccinated,
which limited the power to detect interactions between MMR
vaccination and PFAS concentrations. Therefore, the present
hypothesis about MMR vaccination modifying the association
between PFAS and asthma needs to be reexamined in popula-
tions with a larger number of MMR-unvaccinated children. In
addition, this study conducted a large number of analyses,
which increased the risk of chance findings. Therefore, it did
not look for single significant associations but rather patterns
in the associations.
As common in cohort studies, follow-up was not complete,
and this study compensated for missing data by multiple imputa-
tions. Assuming that data were missing at random, this approach
would be expected to produce more correct estimates of the true
associations (Azur et al. 2011). However, those cohort members
who did not provide information on history of measles infection
had to be excluded. They differed from those included with
regard to maternal serum-PFAS concentrations and asthma at
age 13, and one cannot rule out the possibility of some selection
bias. However, with 87% of the original cohort included in the
present study, it is believed that any potential bias was minimal.
These analyses showed that some confounding did occur, but
only marginally affected the results. However, in observational
studies, the possibility of residual confounding can never be
excluded.
Imprecision of the asthma measures must also be considered.
At age 13, questionnaire data about asthma have been shown to
have a high sensitivity and specificity in relation to clinical
asthma (Fuso et al. 2000), but this measure is probably less pre-
cise at age 5 due to difficulties in distinguishing asthma from
bronchitis. Any misclassification is, however, unlikely to be asso-
ciated with the PFAS exposure or misclassification of PFAS
exposure; therefore any bias likely would have been toward null
(Kristensen 1992).
Overall, prenatal PFAS exposure did not seem to affect the
risk of childhood asthma or allergy. Much previous research has
focused on prenatal exposure, but both the pre- and postnatal
periods are known to be important in establishing an immune
deviation from TH2 to TH1-skewed immunity (Romagnani 2014),
and in this study, associations were found only with postnatal
exposure. In addition, it has been established that children are
highly exposed to PFAS in early life through breastfeeding
(Mogensen et al. 2015), emphasizing the need to further study
the effects of postnatal PFAS exposure.
Table 5. OR for history of allergic and nonallergic asthma associated with a doubling of serum PFAS concentrations at age 5.
Age 5 Age 13
Age 5
PFAS
MMR vaccination
before age 5
Atopic asthmaa
N ¼ 494
Nonatopic asthmab
N ¼ 511
Atopic asthmac
N ¼ 456
Nonatopic asthmad
N ¼ 443
OR (95% CI) pi OR (95% CI) pi OR (95% CI) pi OR (95% CI) pi
PFHxS no 9.30 (1.20; 72.09) 0.02 1.66 (0.32; 8.71) 0.36 1.86 (0.52; 6.69) 0.29 3.31 (0.36; 30.74) 0.26
yes 0.80 (0.47; 1.38) 0.75 (0.48; 1.17) 0.91 (0.58; 1.42) 0.90 (0.52; 1.55)
PFOS no 53.10 (1.50; 1881.81) 0.04 0.08 (0.00; 27.08) 0.47 2.64 (0.24; 29.32) 0.27 8.19 (0.04; 1743.69) 0.55
yes 1.16 (0.44; 3.03) 0.73 (0.34; 1.58) 0.65 (0.29; 1.49) 1.56 (0.65; 3.77)
PFOA no 46.98 (1.26; 1747.34) 0.02 1.20 (0.06; 64.44) 0.62 6.40 (0.80; 50.97) 0.03 20.94 (0.34; 1295.34) 0.12
yes 0.57 (0.19; 1.66) 0.79 (0.37; 1.72) 0.57 (0.25; 1.31) 0.75 (0.29; 1.95)
PFNA no 75.81 (1.24; 4636.88) 0.02 4.24 (0.28; 63.54) 0.17 6.99 (1.06; 45.86) 0.02 14.16 (0.05; 3837.15) 0.34
yes 0.61 (0.25; 1.52) 0.62 (0.32; 1.18) 0.59 (0.30; 1.15) 0.92 (0.45; 1.88)
PFDA no 18.42 (2.02; 168.04) <0.01 1.72 (0.30; 9.66) 0.37 2.43 (0.69; 8.56) 0.05 1.82 (0.16; 20.17) 0.53
yes 0.52 (0.25; 1.05) 0.75 (0.45; 1.23) 0.63 (0.36; 1.10) 0.83 (0.48; 1.44)
Missing values were imputed using multiple imputation. All analyses were adjusted for family history of eczema in children, allergic eczema and hay fever, maternal
pre-pregnancy BMI, maternal smoking during pregnancy, sex, duration of breastfeeding, fish intake at age 5, number of siblings, daycare attendance at age 5, birth
weight, and family history of chronic bronchitis/asthma.
aBoth asthma and allergy at age 5.
bAsthma but not allergy at age 5.
cBoth asthma and positive skin prick test at age 13.
dAsthma but no positive skin prick test at age 13.
ip-value for PFAS/MMR vaccination interaction.
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Among the MMR-unvaccinated children, stronger associations
were found between PFAS concentrations and asthma than
between PFAS and other allergic diseases, and stronger associa-
tions were observed for atopic than for nonatopic asthma. This
indicated that PFAS exposure may affect development of allergy.
However, given the small number of unvaccinated children, these
findings should be interpreted with caution.
Conclusions
Serum PFAS concentrations at age 5 years were associated with
increased odds of asthma at ages 5 and 13 years among MMR-
unvaccinated children. The associations were reversed among
MMR-vaccinated children. Similar analyses failed to identify any
association with prenatal PFAS exposure. These findings suggest
that MMR vaccination should be considered as a potential effect-
modifier in studies of adverse effects of PFAS on immune func-
tions, but larger studies are needed to support the current
findings.
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Appendix A
Imputation models.
Modela Use of data from the model Variables included in the imputation model Interactions
1 All analyses except associations
between PFASs and allergy
(questionnaire) at age 13
and atopic eczema at age
13
Binaryb:
MMR vaccination, parental smoking in the home at ages 5 and 13,
use of daycare at age 5, has furry pets at age 13, father’s primary
education, whether the child had lived abroad between ages 7
and 13, asthma at age 5, allergy at age 5, asthma at age 13, posi-
tive SPT at age 13, rhinoconjunctivitis at age 13
Ordered categoricalc:
Number of siblings, weekly maternal fish dinners, weekly fish dinners
at ages 5 and 13
Nonordered categoricald:
Family history of chronic bronchitis or asthma, family history of
eczema in children, allergic eczema and hay fever, family history
of allergy
Continuous with truncatione:
Total months of breastfeeding
Continuousf:
Maternal PFHxS, PFOS, PFOA, PFNA and PFDA, child PFHxS, PFOS,
PFOA, PFNA and PFDA at age 5, child PFHxS, PFOS, PFOA, PFNA
and PFDA at age 13, umbilical cord IgE, IgE at age 7
Complete (no missing):
Sex, premature birth, birth season, birth weight, maternal pre-preg-
nancy BMI, maternal smoking during pregnancy, maternal parity
Interactions between MMR vaccination
and each of the variables PFHxS,
PFOS, PFOA, PFNA, and PFDA at age
5 were included in the imputation of
asthma at age 5, allergy at age 5,
asthma at age 13
2 Analyses of association
between:
- all PFASs and allergy (ques-
tionnaire) at age 13
- maternal PFASsþ PFASs at
age 5 and eczema at age 13
- PFOS, PFOA, PFNA, and PFDA
at age 13 and eczema at
age 13
All variables from model 1 except asthma at age 13, positive SPT at
age 13, and rhinoconjunctivitis at age 13
Binaryb:
Allergy (questionnaire) at age 13 and atopic eczema at age 13
Interactions between MMR vaccination
and each of the variables PFOS,
PFOA, PFNA, and PFDA at age 13
were included in the imputation of
eczema (age 13)
3 Analyses of association
between PFHxS at age 13
and eczema at age 13
All variables from model 1 except asthma at age 13 and positive
SPT at age 13
Binaryb:
Atopic eczema at age 13
An interaction between MMR vaccination
and PFHxS at age 13 were included
in the imputation of eczema (age 13)
aWe were unable to create an imputation model including all allergy measures at age 13, and data were therefore imputed in three different models
bBinary variables were imputed using logistic regression
cOrdered categorical variables were imputed using ordered logistic regression
dNonordered categorical variables were imputed using multinomial logistic regression
eDuration of breastfeeding was imputed using linear regression left truncated at zero
fOther continuous variables were imputed using classic linear regression.
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Appendix C
Distributions of PFASs by MMR vaccination status at age 5 and asthma status at ages 5 and 13 years (pre-imputation).
MMR vaccinated MMR unvaccinated
Age 5 asthma
Median (min; max)
No asthma at age 5
Median (min; max)
Age 5 asthma
Median (min; max)
No asthma at age 5
Median (min; max)
Maternal PFASs (ng/mL) N ¼ 69 N ¼ 426 N ¼ 8 N ¼ 13
PFHxS 4.2 (1.0; 26.5) 4.6 (0.6; 25.7) 3.0 (1.3; 9.0) 6.2 (1.3; 11.7)
PFOS 28.4 (10.6; 66.7) 27.4 (9.4; 68.8) 28.3 (15.9; 34.0) 24.0 (15.4; 36.4)
PFOA 3.6 (1.3; 6.2) 3.2 (0.8; 8.4) 2.8 (1.3; 4.0) 3.5 (2.1; 4.6)
PFNA 0.6 (0.2; 1.9) 0.6 (0.2; 2.5) 0.7 (0.3; 1.1) 0.6 (0.3; 0.8)
PFDA 0.3 (0.1; 0.8) 0.3 (0.0; 1.2) 0.3 (0.1; 0.7) 0.3 (0.2; 0.5)
Age 5 PFASs (ng/mL) N ¼ 66 N ¼ 427 N ¼ 6 N ¼ 14
PFHxS 0.6 (0.0; 3.0) 0.6 (0.1; 19.5) 1.0 (0.3; 1.3) 0.5 (0.2; 1.6)
PFOS 16.2 (3.3; 33.3) 17.1 (6.2; 48.2) 18.7 (9.2; 27.2) 14.1 (8.8; 27.8)
PFOA 4.0 (0.8; 7.9) 4.0 (1.5; 15.4) 5.0 (3.6; 11.4) 3.5 (2.7; 7.3)
PFNA 0.9 (0.5; 3.2) 1.0 (0.4; 6.2) 1.3 (0.6; 3.9) 0.8 (0.5; 1.6)
PFDA 0.3 (0.1; 0.8) 0.3 (0.1; 1.2) 0.4 (0.1; 0.7) 0.2 (0.1; 0.8)
Age 13 asthma
Median (min; max)
No asthma at age 13
Median (min; max)
Age 13 asthma
Median (min; max)
No asthma at age 13
Median (min; max)
Maternal PFASs (ng/mL) N ¼ 73 N ¼ 372 N ¼ 9 N ¼ 9
PFHxS 4.3 (0.7; 26.5) 4.6 (0.6; 25.7) 3.0 (1.3; 9.0) 8.3 (1.3; 11.7)
PFOS 28.0 (15.8; 66.7) 27.5 (9.4; 57.0) 30.6 (15.9; 36.4) 21.4 (15.4; 33.0)
PFOA 3.5 (1.1; 6.5) 3.2 (0.8; 8.4) 3.8 (1.3; 4.1) 2.8 (2.1; 4.0)
PFNA 0.6 (0.3; 1.9) 0.6 (0.2; 1.8) 0.8 (0.3; 1.1) 0.6 (0.3; 0.6)
PFDA 0.3 (0.1; 0.8) 0.3 (0.0; 0.7) 0.3 (0.1; 0.7) 0.3 (0.2; 0.3)
Age 5 PFASs (ng/mL) N ¼ 70 N ¼ 376 N ¼ 7 N ¼ 10
PFHxS 0.6 (0.0; 1.6) 0.6 (0.1; 19.5) 0.6 (0.3; 1.3) 0.5 (0.2; 1.6)
PFOS 16.5 (3.3; 31.3) 17.1 (6.2; 40.8) 18.6 (9.2; 27.8) 13.1 (10.4; 23.3)
PFOA 4.0 (0.8; 7.9) 4.0 (1.3; 15.4) 5.0 (3.6; 11.4) 3.1 (2.7; 7.3)
PFNA 0.9 (0.5; 3.1) 1.0 (0.4; 5.3) 1.2 (0.5; 3.9) 0.8 (0.5; 1.6)
PFDA 0.3 (0.1; 1.0) 0.3 (0.1; 1.2) 0.3 (0.1; 0.7) 0.2 (0.1; 0.8)
Age 13 PFASs (ng/mL) N¼ 73 N ¼ 392 N ¼ 8 N ¼ 10
PFHxS 0.4 (0.1; 1.2) 0.4 (0.1; 4.1) 0.4 (0.2; 0.7) 0.3 (0.2; 0.6)
PFOS 6.8 (1.5; 14.0) 6.7 (1.0; 16.6) 6.7 (3.9; 9.1) 6.4 (3.5; 8.4)
PFOA 2.0 (0.7; 4.0) 2.0 (0.6; 6.1) 2.1 (1.2; 3.5) 2.0 (1.1; 3.0)
PFNA 0.7 (0.2; 1.7) 0.7 (0.2; 2.1) 0.7 (0.3; 1.2) 0.7 (0.4; 0.9)
PFDA 0.3 (0.1; 0.8) 0.3 (0.1; 1.2) 0.2 (0.2; 0.7) 0.3 (0.1; 0.5)
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